Enliven Therapeutics, Inc.ELVNNASDAQ
Loading
Year-over-year free cash flow growth rate
Percentile
P33
Within normal range
vs 5Y Ago
-1x
Contraction
Streak
2 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q4 2025 | -19.28% |
| Q3 2025 | 22.78% |
| Q2 2025 | 28.79% |
| Q1 2025 | -40.37% |
| Q4 2024 | -40.84% |
| Q3 2024 | 40.23% |
| Q2 2024 | 12.59% |
| Q1 2024 | -87.11% |
| Q4 2023 | 21.46% |
| Q3 2023 | -31.09% |
| Q2 2023 | 41.86% |
| Q1 2023 | -1010.37% |
| Q4 2022 | 70.90% |
| Q3 2022 | 13.01% |
| Q2 2022 | 29.64% |
| Q1 2022 | 15.46% |
| Q4 2021 | -14.53% |
| Q3 2021 | -5.17% |
| Q2 2021 | 20.47% |
| Q1 2021 | -57.68% |
| Q4 2020 | 20.11% |
| Q3 2020 | -11.69% |
| Q2 2020 | 2.92% |
| Q1 2020 | -18.65% |
| Q4 2019 | -26.87% |
| Q3 2019 | -21.23% |
| Q2 2019 | -117.24% |
| Q1 2019 | 0.00% |